S.Biomedics Co., Ltd. (KOSDAQ:304360)

Market Cap	344.31B +38.2%
Revenue (ttm)	16.55B +20.5%
Net Income	-8.12B
EPS	-684.07
Shares Out	12.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,484
Average Volume	78,752
Open	28,550
Previous Close	28,850
Day's Range	26,500 - 28,650
52-Week Range	17,930 - 42,600
Beta	n/a
RSI	35.79
Earnings Date	Apr 6, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration...

• Founded: 2005
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 304360

Financial Performance

In 2025, S.Biomedics's revenue was 16.55 billion, an increase of 20.49% compared to the previous year's 13.73 billion. Losses were -8.12 billion, 21.4% more than in 2024.